Trial Profile
A Phase II Study of Olaparib and Durvalumab (MEDI 4736) in Patients With IDH-Mutated Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Astrocytoma; Biliary cancer; Brain metastases; Cholangiocarcinoma; Glioblastoma; Glioma; Oligodendroglioma; Solid tumours
- Focus Therapeutic Use
- Acronyms SOLID
- 27 Jun 2023 Status changed from recruiting to discontinued.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 08 Jan 2023 Planned number of patients changed from 78 to 58.